By Colin Kellaher
Exelixis has won U.S. Food and Drug Administration expanded approval of its Cabometyx cancer drug for certain patients with advanced neuroendocrine tumors.
Exelixis on Wednesday said the approval covers Cabometyx for patients 12 and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors.
The Alameda, Calif., oncology company said the green light makes Cabometyx the first and only systemic treatment that is FDA-approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status.
Neuroendocrine tumors are heterogeneous tumors that arise from the neuroendocrine cells of the digestive tract and other organs, such as the lung and pancreas, and most patients with advanced disease face a poor prognosis, Exelixis said.
The company's cabozantinib franchise, anchored by Cabometyx, generated $1.81 billion in U.S. net product revenue last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 26, 2025 09:46 ET (13:46 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.